查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016540

阿茲海默症治療市場報告：按藥物類別、分銷管道和地區分類（2026-2034 年）

Alzheimer's Drugs Market Report by Drug Class (Donepezil, Galantamine, Rivastigmine, Memantine, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others), and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球阿茲海默症治療市場規模達85億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到130億美元，2026年至2034年的複合年成長率為4.67% 。阿茲海默症率的上升、藥物研發的諸多進展以及公共和私人對神經退化性疾病研究投入的增加是推動市場成長的主要因素。

阿茲海默症藥物是指專門用於緩解阿茲海默症症狀或延緩其進展的藥物和治療方法。阿茲海默症是一種常見的神經退化性疾病，主要影響認知功能。這些藥物旨在解決大腦中潛在的病理學變化，例如阿茲海默症的特徵性病變—澱粉樣斑塊和Tau蛋白纖維的累積。它們主要分為兩大類：膽鹼酯酶抑制劑和NMDA受體拮抗劑。膽鹼酯酶抑制劑，如多奈哌齊、Rivastigmine的明和Galantamine，透過提高大腦中神經傳導物質的水平來暫時改善認知功能。 NMDA受體拮抗劑，例如Memantine，透過調節麩胺酸活性來緩解認知和行為症狀。

阿茲海默症率的不斷上升，以及對有效治療方法的迫切需求，將推動阿茲海默症治療市場在預測期內的成長。此外，神經科學的許多進展以及對該疾病潛在機制的深入理解，促使主要企業加強研發投入，這將有助於發現潛在的治療方法，並對市場成長產生正面影響。同時，政府和機構對神經退化性疾病研發投入的增加，也為藥物研發創造了有利環境，促進了市場成長。此外，人口老化，尤其是在已開發地區，也推動了市場成長，因為老年人更容易患上阿茲海默症。最後，新藥和治療方法的監管核准不斷增加，為製藥公司進入市場並擴大市場佔有率創造了機會，這也促進了市場成長。

阿茲海默症治療市場的趨勢和促進因素

該疾病盛行率不斷上升

阿茲海默症盛行率的上升是市場成長的主要驅動力之一。這主要是由於全球人口老化所致。隨著人們壽命的延長，包括阿茲海默症在內的與老齡化相關的神經退化性疾病的發生率正在激增。這種人口結構的變化給全球醫療保健系統帶來了日益沉重的負擔，並增加了對有效治療方法的需求。製藥公司正透過投資研發能夠緩解症狀或延緩疾病進展的藥物來滿足這項需求。此外，隨著人們對阿茲海默症的認知不斷提高以及早期診斷的普及，盛行率也不斷上升。因此，盛行率的上升正在推動市場發展，並凸顯了開展研發以應對阿茲海默症帶來的醫療保健挑戰的緊迫性。

調查進展迅速

我們對阿茲海默症分子和細胞層面理解的不斷深入是推動市場發展的關鍵因素。研究人員正在揭示該疾病背後的複雜機制，包括澱粉樣斑塊和Tau蛋白神經纖維纏結在腦退化中的作用。這些發現為藥物研發提供了寶貴的標靶。此外，基因研究正在揭示增加阿茲海默症易感性的遺傳因素，從而進一步指導藥物研發工作。基因組學、神經影像學和生物標記分析等最尖端科技正在加速臨床試驗和藥物療效評估。這些以研究主導的進展對於擴大和提高阿茲海默症候選藥物的療效至關重要，並為改善患者預後帶來了希望。

擴大政府資金和支持

世界各國政府和醫療機構日益認知到阿茲海默症是一項公共衛生危機。該疾病巨大的經濟和社會影響，包括給看護者帶來的負擔和醫療保健成本，正推動阿茲海默症症研究和開發舉措的資金投入不斷增加。政府津貼、研究夥伴關係以及對製藥公司的獎勵也日益普遍。這些財政支持促進了正在進行的研究，並鼓勵製藥業投資於阿茲海默症症療法的研發。此外，監管機構正在簡化阿茲海默症症療法的核准流程，加快產品上市速度。在這種公私合作的環境下，製藥公司被鼓勵進行創新，並將有效的阿茲海默症療法推向市場，以滿足全球迫切的醫療保健需求。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球阿茲海默症治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類別分類

  • 多奈哌齊
  • Galantamine
  • Rivastigmine
  • Memantine
  • 其他

第7章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 網路商店
  • 其他

第8章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第9章 SWOT 分析

第10章：價值鏈分析

第11章：波特五力分析

第12章：價格分析

第13章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Abbvie Inc.
    • AstraZeneca PLC
    • Biogen Inc.
    • Daiichi Sankyo Company Limited
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • H. Lundbeck A/S
    • F. Hoffmann-La Roche AG
    • Merck & Co. Inc.
    • Novartis AG
    • Ono Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Limited
Product Code: SR112026A2695

The global Alzheimer's drugs market size reached USD 8.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 13.0 Billion by 2034, exhibiting a growth rate (CAGR) of 4.67% during 2026-2034. The rising prevalence of Alzheimer's disease, numerous advancements in drug development, and increasing public and private funding for neurodegenerative disease research are some of the major factors propelling the market.

Alzheimer's drugs refer to pharmaceutical compounds and therapies specifically designed to mitigate the symptoms or slow the progression of Alzheimer's disease, a prevalent neurodegenerative disorder that primarily affects cognitive functions. They aim to address the underlying pathophysiological changes in the brain, such as the accumulation of amyloid plaques and tau tangles, which are characteristic of Alzheimer's disease. They fall into two main categories, including cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, like donepezil, rivastigmine, and galantamine, work by boosting the levels of neurotransmitters in the brain, enhancing cognitive function temporarily. NMDA receptor antagonists, such as memantine, regulate glutamate activity, aid in providing relief from cognitive and behavioral symptoms.

The rising prevalence of Alzheimer's disease that necessitates effective treatments will stimulate the growth of the Alzheimer's drugs market during the forecast period. Moreover, the increasing research and development efforts by key players due to numerous advancements in neuroscience and a deeper understanding of the disease's underlying mechanisms, leading to the discovery of potential therapeutic agents, is positively influencing market growth. Additionally, the rise in funding allocations by governments and organizations for neurodegenerative disease research, facilitating a conducive environment for drug development, has catalyzed market growth. Besides this, the expanding aging population, particularly in developed regions, is propelling market growth as the elderly are more susceptible to Alzheimer's disease. Furthermore, the escalating regulatory approvals for novel drugs and therapies that creates opportunities for pharmaceutical companies to enter and expand their presence is contributing to market growth.

Alzheimer's Drugs Market Trends/Drivers

Rising prevalence of the disease

The escalating prevalence of Alzheimer's disease is one of the key factors supporting the market growth. This can be attributed to the rapidly aging population worldwide. As people live longer, the incidence of age-related neurodegenerative disorders, including Alzheimer's, has surged. This demographic shift places an ever-increasing burden on global healthcare systems and necessitates effective treatments. Pharmaceutical companies are responding to this demand by investing in the development of drugs that can alleviate symptoms or potentially slow down disease progression. Moreover, heightened awareness and early diagnosis contribute to the rising prevalence as more cases are identified. As a result, the prevalence factor drives the market and underscores the urgent need for research and innovation to address the healthcare challenges posed by Alzheimer's disease.

Rapid advancements in research

Advances in the understanding of Alzheimer's disease at the molecular and cellular levels are pivotal drivers in the market. Researchers are unraveling the complex mechanisms behind the disease, including the role of amyloid plaques and tau protein tangles in brain degeneration. These insights provide valuable targets for drug development. Additionally, genetics research is revealing the hereditary factors that increase susceptibility to Alzheimer's, further guiding drug discovery efforts. Cutting-edge technologies, such as genomics, neuroimaging, and biomarker analysis, are facilitating clinical trials and drug efficacy assessments. These research-driven developments are instrumental in expanding the repertoire of potential Alzheimer's drugs and enhancing their effectiveness, offering hope for improved patient outcomes.

Increasing government funding and support

Governments and healthcare organizations across the globe are increasingly recognizing Alzheimer's disease as a public health crisis. The substantial economic and social impact of the disease, including caregiver burden and healthcare costs, has led to a rise in funding for Alzheimer's research and drug development initiatives. Government grants, research partnerships, and incentives for pharmaceutical companies have become more prevalent. This financial support bolsters ongoing research efforts and encourages the pharmaceutical industry to invest in Alzheimer's drug development. Moreover, regulatory agencies are streamlining approval processes for Alzheimer's drugs, facilitating faster market entry. In this collaborative environment of public and private sector support, pharmaceutical companies are incentivized to innovate and bring effective Alzheimer's treatments to the market, addressing a pressing global healthcare need.

Alzheimer's Drugs Industry Segmentation

This report provides an analysis of the key trends in each sub-segment of the global Alzheimer's drugs market report, along with forecasts at the global, regional and country levels for 2026-2034. The report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class

  • Donepezil
  • Galantamine
  • Rivastigmine
  • Memantine
  • Others

Donepezil represents the most popular drug class

Donepezil is a medication categorized as a cholinesterase inhibitor, commonly used in the treatment of Alzheimer's disease. It works by increasing the levels of certain neurotransmitters in the brain, helping to improve cognitive function and alleviate some of the symptoms associated with Alzheimer's, such as memory loss, confusion, and problems with thinking and reasoning.

Furthermore, donepezil, along with similar drugs like rivastigmine and galantamine, plays a pivotal role in driving the market growth. These drugs are often prescribed to patients with Alzheimer's to manage their symptoms, providing relief and enhancing their quality of life. As the global prevalence of Alzheimer's continues to rise, there is an increasing demand for such drugs. This growing demand encourages pharmaceutical companies to invest in research and development, striving to innovate and improve upon existing treatments, thus contributing to the expansion of the Alzheimer's drugs market.

Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores
  • Others

Hospital pharmacy accounts for the majority of the market share

Hospital pharmacy refers to the specialized pharmacy practice within healthcare institutions, such as hospitals and medical centers. Its primary role is to ensure the safe and effective use of medications for inpatients and outpatients. Hospital pharmacists work closely with healthcare teams to provide medication therapy management, including drug dispensing, monitoring, and patient education. Hospital pharmacies play a crucial role in fueling the market expansion as they are instrumental in the distribution and administration of Alzheimer's medications. They serve as a pivotal link between pharmaceutical companies, healthcare providers, and patients, ensuring that Alzheimer's drugs reach the right individuals at the right time.

Moreover, hospital pharmacists contribute to patient education and adherence, optimizing the effectiveness of these drugs. The growth of the Alzheimer's drugs market is related to the efficient and patient-focused services provided by hospital pharmacies, as they facilitate the delivery of these vital medications to those in need.

Breakup by Region

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest share in the market since the region has a significant and growing geriatric population, and Alzheimer's primarily affects older individuals. This demographic trend increases the demand for Alzheimer's drugs. Moreover, North America boasts a robust healthcare infrastructure, which includes advanced research facilities and pharmaceutical companies at the forefront of Alzheimer's drug development. These companies conduct clinical trials and research initiatives that contribute to innovation in the field.

Additionally, regulatory bodies like the FDA in the United States play a crucial role in drug approvals, setting the standard for global markets. Apart from this, North America has a high level of awareness about Alzheimer's disease, leading to early diagnosis and greater use of available treatments. Furthermore, North America's well-established healthcare reimbursement systems and patient advocacy groups actively support access to Alzheimer's drugs, fostering an environment that drives market growth and encourages pharmaceutical innovation in the region.

Competitive Landscape

Key players in the Alzheimer's drugs industry have been instrumental in driving recent innovations. Notably, a groundbreaking FDA-approved drug from one of these major pharmaceutical companies directly targets amyloid plaques, marking a significant advancement in Alzheimer's treatment. Other key players are pioneering therapies that enhance amyloid clearance and simultaneously address tau pathology, both of which have shown promise in clinical trials. Beyond traditional drug development, these companies are exploring innovative approaches, including anti-inflammatory drugs, to combat neuroinflammation associated with Alzheimer's. Additionally, digital health technologies have been integrated into their strategies, with the introduction of cognitive assessment tools and digital biomarkers, revolutionizing early detection and monitoring of Alzheimer's. The efforts of these industry players signify a dynamic and comprehensive approach to tackle this complex neurodegenerative disease.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AbbVie Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Daiichi Sankyo Company Limited
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc
  • Teva Pharmaceutical Industries Limited

Key Questions Answered in This Report

  • How has the global alzheimer's drugs market performed so far and how will it perform in the coming years ?
  • What has been the impact of COVID-19 on the global alzheimer's drugs market ?
  • What are the key regional markets ?
  • What is the breakup of the market based on the drug class ?
  • What is the breakup of the market based on the distribution channel ?
  • What are the various stages in the value chain of the industry ?
  • What are the key driving factors and challenges in the industry ?
  • What is the structure of the global alzheimer's drugs market and who are the key players ?
  • What is the degree of competition in the industry ?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Alzheimer's Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Donepezil
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Galantamine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Rivastigmine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Memantine
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbvie Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca PLC
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Biogen Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Daiichi Sankyo Company Limited
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Eisai Co. Ltd.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Eli Lilly and Company
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 H. Lundbeck A/S
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 F. Hoffmann-La Roche AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Novartis AG
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Ono Pharmaceutical Co. Ltd.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Pfizer Inc.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
    • 13.3.13 Teva Pharmaceutical Industries Limited
      • 13.3.13.1 Company Overview
      • 13.3.13.2 Product Portfolio
      • 13.3.13.3 Financials
      • 13.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Alzheimer's Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Alzheimer's Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Alzheimer's Drugs Market: Breakup by Drug Class (in %), 2025
  • Figure 4: Global: Alzheimer's Drugs Market: Breakup by Distribution Channel (in %), 2025
  • Figure 5: Global: Alzheimer's Drugs Market: Breakup by Region (in %), 2025
  • Figure 6: Global: Alzheimer's Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 7: Global: Alzheimer's Drugs (Donepezil) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Alzheimer's Drugs (Donepezil) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Alzheimer's Drugs (Galantamine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Alzheimer's Drugs (Galantamine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Alzheimer's Drugs (Rivastigmine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Alzheimer's Drugs (Rivastigmine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Alzheimer's Drugs (Memantine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Alzheimer's Drugs (Memantine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Alzheimer's Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Alzheimer's Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Alzheimer's Drugs (Hospital Pharmacy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Alzheimer's Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Alzheimer's Drugs (Retail Pharmacy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Alzheimer's Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Alzheimer's Drugs (Online Stores) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Alzheimer's Drugs (Online Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Alzheimer's Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Alzheimer's Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: North America: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: North America: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: United States: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: United States: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Canada: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Canada: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Asia Pacific: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Asia Pacific: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: China: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: China: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Japan: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Japan: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: India: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: India: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: South Korea: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: South Korea: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Australia: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Australia: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Indonesia: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Indonesia: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Others: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Europe: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Europe: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Germany: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Germany: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: France: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: France: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: United Kingdom: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: United Kingdom: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Italy: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Italy: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Spain: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Spain: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Russia: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Russia: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Others: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Latin America: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Latin America: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Brazil: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Brazil: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Mexico: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Mexico: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Others: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Middle East and Africa: Alzheimer's Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Middle East and Africa: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Global: Alzheimer's Drugs Industry: SWOT Analysis
  • Figure 74: Global: Alzheimer's Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Alzheimer's Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Alzheimer's Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Alzheimer's Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Alzheimer's Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 4: Global: Alzheimer's Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 5: Global: Alzheimer's Drugs Market: Competitive Structure
  • Table 6: Global: Alzheimer's Drugs Market: Key Players